Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-24
2005-05-24
Shah, Mukund J. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S284000, C544S293000, C544S119000, C514S266200, C514S266210, C514S266230, C514S266240
Reexamination Certificate
active
06897214
ABSTRACT:
The invention concerns quinazoline derivatives of the formula Iwherein X1is a direct link or a group such as CO, C(R2)2and CH(OR2);wherein Q1is phenyl, naphthyl or a 5- or 6-membered heteroaryl moiety and Q1optionally bears up to 3 substituents;wherein m is 1 or 2 and each R1may be a group such as hydrogen, halogeno and trifluoromethyl; andwherein Q2may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q2optionally bears up to 3 substituents;or a pharmaceutically-acceptable salt thereof;processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer.
REFERENCES:
patent: 3266990 (1966-08-01), Lutz et al.
patent: 4343940 (1982-08-01), Kreighbaum et al.
patent: 5457105 (1995-10-01), Barker
patent: 5475001 (1995-12-01), Barker
patent: 5580870 (1996-12-01), Barker et al.
patent: 5770599 (1998-06-01), Gibson
patent: 5821246 (1998-10-01), Brown et al.
patent: 5866572 (1999-02-01), Barker
patent: 5932574 (1999-08-01), Baker
patent: 5955464 (1999-09-01), Barker
patent: 6015814 (2000-01-01), Barker
patent: 6225318 (2001-05-01), Sobolov-Jaynes et al.
patent: 2086968 (1993-01-01), None
patent: 19528672 (1997-02-01), None
patent: 0 326 307 (1989-02-01), None
patent: 0 326 330 (1989-08-01), None
patent: 0 520 722 (1992-12-01), None
patent: 0 566 226 (1993-10-01), None
patent: 0 602 851 (1994-06-01), None
patent: 0 635 498 (1995-01-01), None
patent: 0 635 507 (1995-01-01), None
patent: 0 682 027 (1995-11-01), None
patent: 2 033 894 (1980-05-01), None
patent: 2 160 201 (1985-12-01), None
patent: WO 9214716 (1992-09-01), None
patent: WO 9220642 (1992-11-01), None
patent: WO 9506648 (1995-03-01), None
patent: WO 9515758 (1995-06-01), None
patent: WO 9515952 (1995-06-01), None
patent: WO 9519169 (1995-07-01), None
patent: WO 9519774 (1995-07-01), None
patent: Wo 9519970 (1995-07-01), None
patent: WO 9521613 (1995-08-01), None
patent: WO 9523141 (1995-08-01), None
patent: WO 9524190 (1995-09-01), None
patent: WO 9607657 (1996-03-01), None
patent: WO 9609294 (1996-03-01), None
patent: WO 9615118 (1996-05-01), None
patent: WO 9616960 (1996-06-01), None
patent: WO 9629331 (1996-09-01), None
patent: WO 9630347 (1996-10-01), None
patent: WO 9631510 (1996-10-01), None
patent: WO 9633977 (1996-10-01), None
patent: WO 9633978 (1996-10-01), None
patent: WO 9633979 (1996-10-01), None
patent: WO 9633980 (1996-10-01), None
patent: WO 9633981 (1996-10-01), None
patent: WO 9634867 (1996-11-01), None
patent: WO 9635689 (1996-11-01), None
patent: WO 9639145 (1996-12-01), None
patent: WO 9640142 (1996-12-01), None
patent: WO 9640648 (1996-12-01), None
patent: WO 9703069 (1997-01-01), None
patent: WO 9802434 (1998-01-01), None
Bridges, “The current status of tyrosine kinase inhibitors: do the dairylamine inhibitors of the EGF receptor represent a new beginning?,” Exp.Opin.Ther.Patents (1995), 5(12): 1245-1257, Editorial, Oncologic, Endocrine & Metabolic, 1995 Ashley Publications Ltd ISSN 1354-3776.
Bridges, et al., “Enantioselective Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase by 4-(a-Phenethylamino)quinazolines,” Bioorganic & Medicinal Chemistry, vol. 3, No. 12, pp. 1651-1656, 1995.
Buchdunger et al., “4,5-Dianilinophthalimide: A protein-tyrosine kinase inhibitor with selectivity of the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity” Prac. Natl. Acad. Sci., USA, vol. 91, pp. 2334-2338, Mar. 1994, Applied Biological Sciences.
Burke, Jr., “Protein-tyrosine kinase inhibitors,” Drugs of the Future, 1992, vol. 12(2), pp. 119-131.
Dolle, et al., “5,7-Dimethoxy-3-(4-pyridinyl)quinoline Is a Potent and Selective Inhibitor of Human Vascular β-Type Platelet-Derived Growth Factor Receptor Tyrosine Kinase,” J. Med. Chem., 1994, vol. 37, pp. 2627-2629.
Fry et al., “A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase,” SCIENCE, vol. 265, Aug. 19, 1994, pp. 1093-1095.
Iyer, et al., “Studies in Potential Amoebicieds: Part III-Synthesis of 4-Substituted Amino-8-Hydroxy) Quinazolines & 3-Substituted 8-Hydroxy(&8-Methoxy)-4-Quinazolones,” J.Sci.Industr.Res., vol. 15C, Jan. 1956, pp. 1-7.
Kobayashi, Derwent Abstract 82-87077, vol. 6, No. 244, Dec. 1982, JP 57-144266, Sep. 1982, “4-Anilinoquinazoline Derivative, its Preparation and Analgesic and Antiphlogistic Agent Containing Said Derivative as Active Component”. (n.7).
Kyorin, Derwent Abstract 84-53835, JP 59-13765, Jan. 1984, “2-(4-Quinazolinyl)amino benzoic acid derivs. . . having analgesic and antinflammatoryactivities”. (n.8).
Li, et al., Chem.Abs., vol. 92:76445u, 1980, p.674-675.
Lin et al., Chem.Abs., vol. 96:122728w, 1982, p.695.
Maguire, et al., “A New Series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Substituted Quinoline Derivatives,” J. Med. Chem., 1994, vol. 37, pp. pp. 2129-2137.
Rewcastle et al., “Tyrosine Kinase Inhibitors. 5. . . 4-(Phenylamino)quinazolines as Potent. . . Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor,” J. Med. Chem. 1995, vol. 38, pp.3482-3487.
Sankyo and Ube, Derwent Abstract 81-28290, JP 56-20577, Feb. 1981, “4-(N-alkyl:anilino)quinazoline derivs. . . having analgesic and antiinflammatory actions”. (n.9).
Spada, et al., Small molecule inhibitors of tyrosine Kinase activity, Exp.Opin.Ther.Patents (1995), 5(8):805-817, Patent Update, Oncologic, Endocrine & Metabolic, Ashley Publications Ltd ISSN 1354-3776.
Spence, “Inhibitors of Tyrosine Kinase Activity as Anticancer Therapeutics: Recent Developments,” Current Opinion in Therapeutic Patents, Jan. 1993, Patent Update, Anticancers, etc., pp. 3-9, Current Drugs Ltd. ISSN 0962-2594.
Traxler, et al., “Recent advances in protein tyrosine kinase inhibitors,” Drugs of the Future 1995, vol. 20(12,pp. 1261-1274.
Trinks, et al., “Dianilinophthalimides: Potent and Selective, ATP-Competitive Inhibitors of the EGF-Receptor Protein Tyrosine Kinase,” J. Med. Chem., 1994, vol. 37, pp. 1015-1027.
Ward, et al., “Epidermal Growth Factor Rēceptor Tyrosine Kinase—Investigation of Catalytic Mechanism, Structure-Based Searching and Discovery of a Potent Inhibitor,” Biochem.Pharmacology, vol. 48, No. 4, pp. 659-666 (1994).
Barker Andrew John
Johnstone Craig
Liu Hong
Morgan & Lewis & Bockius, LLP
Shah Mukund J.
Zeneca Limited
LandOfFree
Quinazoline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazoline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3403838